Key facts
- It has raised $15.4M; the latest was Later Stage VC in Dec 2024.
- Notable investors include CICC Capital, Dalton Venture, Shanghai Zhangjiang Science & Technology Venture Capital, CICC Private Equity, Changzhou Weichi Investment — 11 tracked in total.
- Status: Privately Held (backing).
Investors
11+- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for VitaVitro
- ·The full record, as it builds
Funding rounds
No funding rounds for VitaVitro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VitaVitro
Developer of assisted reproductive technology intended to solve infertility problem. The company's main business includes the entire process from egg retrieval, freezing, culture to embryo transfer, helping clients get the best quality embryos and increase the pregnancy rate.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2015
- Employees
- 20
- Website
- vitavitro.cn/
- Ownership
- Privately Held (backing)
VitaVitro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VitaVitro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VitaVitro in its N-PORT filings yet. We sweep new filings monthly.